Results 171 to 180 of about 1,132,527 (387)
Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients [PDF]
, 2015 Gregory S. Sawicki +4 more
openalex +1 more source
ChemistryEurope, EarlyView.Following the Danube Flow. The first total syntheses of highly brominated rubrolides T, U, and U‐analog, together with the efficient and divergent syntheses of rubrolides A, D, and P. The dibrominated key intermediate, obtained via a Suzuki‐Miyaura cross‐coupling reaction, is the centerpiece of the synthesis.
Jasmin Janneschütz +7 more
wiley +1 more source
Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis [PDF]
, 2013 Matthew Hurley +2 more
openalex +1 more source
Low Diversity and Instability of the Sinus Microbiota over Time in Adults with Cystic Fibrosis
, 2022 Catherine R. Armbruster +16 more
openalex +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Cystic fibrosis (CF) is a chronic hereditary disease that affects tens of thousands of people worldwide. The introduction of CFTR modulator therapies such as elexacaftor/tezacaftor/ivacaftor (ETI) has significantly improved the quality of life of people with CF.
Alan Shi +3 more
wiley +1 more source
Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients [PDF]
, 2018 Lois W. Martin +10 more
openalex +1 more source
ESC Heart Failure, EarlyView.Abstract Aims Heart–lung transplantation (HLTx) remains a life‐saving intervention for patients with end‐stage cardiopulmonary failure. We retrospectively analysed long‐term HLTx outcomes at our centre to assess survival trends and evaluate the impact of evolving immunosuppressive, surgical and perioperative strategies.
L. Lily Rosenthal +10 more
wiley +1 more source